NCI-2020-03830

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

In this study, researchers are exploring a new medication called DF1001, aiming to understand its safety and effectiveness for patients with locally advanced or metastatic solid tumors. They'll administer increasing doses of DF1001 to find the right amount that balances effectiveness and safety. Additionally, they'll investigate how the medication moves through the body (pharmacokinetics), its impact on the body's biological processes, and its ability to shrink tumors or slow down cancer growth (clinical activity). If the initial phases show promise, the study may expand to focus on specific types of cancer where DF1001 demonstrates potential benefits.

pharmacokinetics: Pharmacokinetics studies how medicines move around in the body, including how they are absorbed, distributed, broken down, and removed.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04143711

Clinical Trial Site: Sinai

To see all available clinical trials click here.